Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S, Aversa F, Tabilio A, Romani L, Martelli M F, Velardi A
Division of Hematology and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Perugia, Italy.
Blood. 2001 Apr 15;97(8):2514-21. doi: 10.1182/blood.v97.8.2514.
In human leukocyte antigen haplotype-mismatched transplantation, extensive T-cell depletion prevents graft-versus-host disease (GVHD) but delays immune recovery. Granulocyte colony-stimulating factor (G-CSF) is given to donors to mobilize stem cells and to recipients to ensure engraftment. Studies have shown that G-CSF promotes T-helper (Th)-2 immune deviation which, unlike Th1 responses, does not protect against intracellular pathogens and fungi. The effect of administration of G-CSF to recipients of mismatched hematopoietic transplants with respect to transplantation outcome and functional immune recovery was investigated. In 43 patients with acute leukemia who received G-CSF after transplantation, the engraftment rate was 95%. However, the patients had a long-lasting type 2 immune reactivity, ie, Th2-inducing dendritic cells not producing interleukin 12 (IL-12) and high frequencies of IL-4- and IL-10-producing CD4(+) cells not expressing the IL-12 receptor beta(2) chain. Similar immune reactivity patterns were observed on exposure of donor cells to G-CSF. Elimination of postgrafting administration of G-CSF in a subsequent series of 36 patients with acute leukemia, while not adversely affecting engraftment rate (93%), resulted in the anticipated appearance of IL-12-producing dendritic cells (1-3 months after transplantation versus > 12 months in transplant recipients given G-CSF), of CD4(+) cells of a mixed Th0/Th1 phenotype, and of antifungal T-cell reactivity in vitro. Moreover, CD4(+) cell counts increased in significantly less time. Finally, elimination of G-CSF-mediated immune suppression did not significantly increase the incidence of GVHD (< 15%). Thus, this study found that administration of G-CSF to recipients of T-cell-depleted hematopoietic transplants was associated with abnormal antigen-presenting cell functions and T-cell reactivity. Elimination of postgrafting administration of G-CSF prevented immune dysregulation and accelerated functional immune recovery.
在人类白细胞抗原单倍型不匹配的移植中,广泛的T细胞清除可预防移植物抗宿主病(GVHD),但会延迟免疫恢复。给予供体粒细胞集落刺激因子(G-CSF)以动员干细胞,并给予受体以确保植入。研究表明,G-CSF促进辅助性T(Th)-2免疫偏移,与Th1反应不同,Th2反应不能抵御细胞内病原体和真菌。研究了对不匹配造血移植受体给予G-CSF对移植结果和功能性免疫恢复的影响。43例急性白血病患者移植后接受G-CSF,植入率为95%。然而,这些患者具有持久的2型免疫反应性,即诱导Th2的树突状细胞不产生白细胞介素12(IL-12),以及高频率产生IL-4和IL-10的CD4(+)细胞不表达IL-12受体β(2)链。供体细胞暴露于G-CSF时也观察到类似的免疫反应模式。在随后的36例急性白血病患者系列中,消除移植后给予的G-CSF,虽然对植入率没有不利影响(93%),但导致预期出现产生IL-12的树突状细胞(移植后1-3个月,而接受G-CSF的移植受体>12个月)、混合Th0/Th1表型的CD4(+)细胞以及体外抗真菌T细胞反应性。此外,CD4(+)细胞计数在显著更短的时间内增加。最后,消除G-CSF介导的免疫抑制并没有显著增加GVHD的发生率(<15%)。因此,本研究发现,对T细胞清除的造血移植受体给予G-CSF与异常的抗原呈递细胞功能和T细胞反应性有关。消除移植后给予的G-CSF可预防免疫失调并加速功能性免疫恢复。